Company / EPS (Diluted)
ENDRA Life Sciences Inc. EPS (Diluted) History
FY2017-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$2.34
FY2020
5-year range
-$3.84 / -$1.95
FY2017-FY2020
Trend
-7.8%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $-1.95 to $-2.34 over the past 2 years.
Based on SEC 10-K filings.
-2.34 in FY2020.
Declined from $-1.95 to $-2.34 over the past 2 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2020, eps (diluted) decreased 7.8% year-over-year.
Company context
Key Data Points
- Altman Z-Score -7.14 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2020 | -$2.34 | -7.8% |
| FY2019 | -$2.17 | -11.3% |
| FY2018 | -$1.95 | +49.2% |
| FY2017 | -$3.84 | - |
As of FY2020 · SEC 10-K · Updated Jun 28, 2026